BOSTON - A federal appeals court panel on April 3 affirmed a $142 million verdict against Pfizer Inc. for off-label marketing of Neurontin to a third-party payer, vacated summary judgment against another four other third-party payers and vacated denial of class certification for three of the payers (In Re Neurontin Marketing and Sales Practices Litigation, Kaiser Foundation Health Plan, Inc., et al. v. Pfizer, Inc., et al., Nos. 11-1904 and 11-2096, 1st Cir.; 2013 U.S. App. LEXIS 6793; In Re Neurontin...(read more)![]()
↧